Protocol Ledger

NCT04985266 · Phase II · RECRUITING

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Can

Interventional Phase II clinical trial protocol NCT04985266 sponsored by Royal Marsden NHS Foundation Trust in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-03-30 Enrollment: 1,100 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04985266
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,100 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04985266
Protocol FieldVerified Registry Value
NCT IdentifierNCT04985266
Consolidated Lead SponsorRoyal Marsden NHS Foundation Trust
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment1,100 participants (ESTIMATED)
Registered Start Date2022-03-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04985266
Hospital Research SiteLocationSite Profile
Institut BergoniéBordeaux, FranceOpen Hospital Dossier ->
Centre Jean PerrinClermont-Ferrand, FranceOpen Hospital Dossier ->
Centre Léon BérardLyon, FranceOpen Hospital Dossier ->
Institut Paoli-CalmettesMarseille, FranceOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI